Major advances in biosimilars have occurred in the last three months, beginning with the FDA Arthritis Advisory Committee voting 21-3 to approve Celltrion’s Inflectra (CT-P13) and ending with the recent approval of Inflectra (generically referred to as infliximab dyyb).
Systemic lupus is a clinically heterogeneous disorder, unified by requisite clinical features and exuberant humoral response to unknown triggers. While the diagnosis is easy, the disease course and management can be complicated and challenging.
One of the hallmarks of aggressive rheumatoid arthritis (RA) is presence of antibodies against citrullinated protein antigens (ACPA).
In a retrospective cohort comparison study, 42,180 rheumatoid arthritis (RA) patients were compared 1:4 with 168,000 normal controls to examine the incidence of new tuberculosis in Taiwan. The RA population included those receiving csDMARDs (36,162), etanercept (3,577), adalimumab (1,67
This week, when the FDA approved the biosimilar drug Inflectra as an alternative to infliximab (Remicade), it was only the second biosimilar to be granted approval in the United States, and was the fi
Methotrexate (MTX) is a highly favored drug in rheumatology. Yet it has numerous nuisance side effects that may limit its use or patient acceptance.
In March 2016, RheumNow published 82 social media “tweets” regarding news, research and teaching points that impact the rheumatology community. These feeds had a reach (impressions) of 86,400 with, 76 mentions, and over 2700 visits to learn on RheumNow.com.
Dr. Jack Cush reviews the rheumatology highlights from the news, media, and journals from this past week:
Lopez and colleagues from Spain have studied the gut microbiome of l
The GAUSS-3 trial, recently published in JAMA, examined cholesterol-lowering interventions in patients with a high LDL (>120 mg/dl) and a history of statin intolerance to 2 or more statins.
At the 2016 World Congress on Osteoarthritis (OARSI) meeting last week, first line results of a novel intraarticular inhibitor of the Wnt pathway (SM04690) in knee osteoarthritis were presented.
It is estimated that 21% of laboratory tests are requested inappropriately. Researchers have explored the impact of educational programs for rheumatologists working at three rheumatology departments in secondary and tertiary care centers in The Netherlands.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
